Bivalirudin Patent Expiration
Bivalirudin is Used for preventing blood clots in patients undergoing percutaneous coronary intervention (PCI). It was first introduced by Sandoz Inc
Bivalirudin Patents
Given below is the list of patents protecting Bivalirudin, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Angiomax Rtu | US11903993 | Ready-to-use bivalirudin compositions | May 20, 2039 | Maia Pharms Inc |
| Angiomax Rtu | US11918622 | Ready-to-use bivalirudin compositions | May 20, 2039 | Maia Pharms Inc |
| Angiomax Rtu | US11992514 | Ready-to-use bivalirudin compositions | May 20, 2039 | Maia Pharms Inc |
| Angiomax Rtu | US12472224 | Ready-To-Use Bivalirudin Compositions | May 20, 2039 | Maia Pharms Inc |
| Angiomax |
US7582727 (Pediatric) | Pharmaceutical formulations of bivalirudin and processes of making the same | Jan 27, 2029 | Sandoz |
| Angiomax |
US7598343 (Pediatric) | Pharmaceutical formulations of bivalirudin and processes of making the same | Jan 27, 2029 | Sandoz |
| Angiomax | US7582727 | Pharmaceutical formulations of bivalirudin and processes of making the same | Jul 27, 2028 | Sandoz |
| Angiomax | US7598343 | Pharmaceutical formulations of bivalirudin and processes of making the same | Jul 27, 2028 | Sandoz |
| Angiomax |
US5196404 (Pediatric) | Inhibitors of thrombin |
Jun 15, 2015
(Expired) | Sandoz |
| Angiomax | US5196404 | Inhibitors of thrombin |
Dec 15, 2014
(Expired) | Sandoz |
Bivalirudin's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Bivalirudin:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| BivaLirudin versUS Heparin in Extracorporeal Membrane Oxygenation | Sydney Local Health District | NA |
RECRUITING
(May 1, 2026)
| PHASE2 |